• Latest Posts

Galapagos Nears First Drug Approval with Phase III Success in Rheumatoid Arthritis

Inflammatory Disease Treatment Backed by €20M Series A

Italian Biotech Raises Big Series A for ‘Gene Therapy 2.0’

Solid Phase II Performance for French Autoimmune Liver Disease Drug


Oxford Biotech Launches with €26M to Target ‘Immunometabolism’

More News! 19 Sep 2018

Argenx Attracts Huge €250M Investment Following Positive Phase II Trial

Sangamo Acquires French Biotech to Develop CAR-T Therapies for Autoimmune Disease

French Lupus Vaccine Ready to Move Into Phase III

German DNA Treatment Reduces Ulcerative Colitis Symptoms

More News! 16 Apr 2018

Epitopes Come to the Rescue for One of the Most Common Autoimmune Diseases